Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17058804rdf:typepubmed:Citationlld:pubmed
pubmed-article:17058804lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:17058804lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:17058804lifeskim:mentionsumls-concept:C0021083lld:lifeskim
pubmed-article:17058804lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:17058804lifeskim:mentionsumls-concept:C1823153lld:lifeskim
pubmed-article:17058804lifeskim:mentionsumls-concept:C1705241lld:lifeskim
pubmed-article:17058804lifeskim:mentionsumls-concept:C0439097lld:lifeskim
pubmed-article:17058804lifeskim:mentionsumls-concept:C2349976lld:lifeskim
pubmed-article:17058804lifeskim:mentionsumls-concept:C1552644lld:lifeskim
pubmed-article:17058804lifeskim:mentionsumls-concept:C1547348lld:lifeskim
pubmed-article:17058804pubmed:issue1lld:pubmed
pubmed-article:17058804pubmed:dateCreated2006-10-23lld:pubmed
pubmed-article:17058804pubmed:abstractTextHuman Vgamma2Vdelta2 T cells recognize nonpeptide antigens derived from pathogenic microbes in a TCR-dependent manner, such as pyrophosphomonoester compounds from mycobacteria and malaria parasite and alkyl amines from Proteus, suggesting that this subset of gamma delta T cells is involved in infectious immunity. The precise recognition mechanism has been delineated using a site-directed mutagenesis strategy based on crystal structure of gamma delta TCR. On the other hand, several lines of evidence indicate that human gamma delta T cells are involved in tumor immunity. Although activated gamma delta T cells exhibit a cytolytic activity against most of tumor cells, only a small fraction of tumor cells, like Burkitt lymphoma cells and multiple myeloid cells, is recognized by human gamma delta T cells in a TCR-dependent manner. This implicates that human gamma delta T cells have two distinct pathways for anti-tumor immunity. One is a natural killer-like pathway and the other is a TCR-dependent pathway. Recently, it was shown that treatment of human tumor cells with nitrogen-containing bisphosphonates, therapeutic drugs for hypercalcemia in malignancy, generated antigenic structure on the surface of tumor cells, which could be recognized by human gamma delta T cells in a TCR-dependent manner. This tumor labeling system may lead to a novel strategy for cancer immunotherapy.lld:pubmed
pubmed-article:17058804pubmed:languageenglld:pubmed
pubmed-article:17058804pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17058804pubmed:citationSubsetIMlld:pubmed
pubmed-article:17058804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17058804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17058804pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17058804pubmed:statusMEDLINElld:pubmed
pubmed-article:17058804pubmed:monthMarlld:pubmed
pubmed-article:17058804pubmed:issn1346-4280lld:pubmed
pubmed-article:17058804pubmed:authorpubmed-author:TanakaYoshima...lld:pubmed
pubmed-article:17058804pubmed:issnTypePrintlld:pubmed
pubmed-article:17058804pubmed:volume46lld:pubmed
pubmed-article:17058804pubmed:ownerNLMlld:pubmed
pubmed-article:17058804pubmed:authorsCompleteYlld:pubmed
pubmed-article:17058804pubmed:pagination11-23lld:pubmed
pubmed-article:17058804pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:meshHeadingpubmed-meshheading:17058804...lld:pubmed
pubmed-article:17058804pubmed:year2006lld:pubmed
pubmed-article:17058804pubmed:articleTitleHuman gamma delta T cells and tumor immunotherapy.lld:pubmed
pubmed-article:17058804pubmed:affiliationLaboratory of Immunology and Cell Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan.lld:pubmed
pubmed-article:17058804pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17058804pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17058804lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17058804lld:pubmed